应用伤害性水平指数(NOX)对睡眠障碍患者乳腺癌根治术后认知功能的影响

注册号:

Registration number:

ChiCTR2300069945 

最近更新日期:

Date of Last Refreshed on:

2023-05-27 19:47:12 

注册时间:

Date of Registration:

2023-03-29 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

应用伤害性水平指数(NOX)对睡眠障碍患者乳腺癌根治术后认知功能的影响

Public title:

The effect of nociceptive level index ( NOX ) on cognitive function of patients with sleep disorders after radical mastectomy for breast cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

应用伤害性水平指数(NOX)对睡眠障碍患者乳腺癌根治术后认知功能的影响

Scientific title:

The effect of nociceptive level index ( NOX ) on cognitive function of patients with sleep disorders after radical mastectomy for breast cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

詹银周 

研究负责人:

詹银周 

Applicant:

Yinzhou Zhan 

Study leader:

Yinzhou Zhan 

申请注册联系人电话:

Applicant telephone:

+86 13750412255

研究负责人电话:

Study leader's
telephone:

+86 13750412255

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

46322137@qq.com

研究负责人电子邮件:

Study leader's E-mail:

46322137@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

汕头市金平区外马路114号

研究负责人通讯地址:

汕头市金平区外马路114号

Applicant address:

Shantou Central Hospital,114 Waima Road, Jingping District, Shantou, Guangdong, China

Study leader's address:

Shantou Central Hospital,114 Waima Road, Jingping District, Shantou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

汕头市中心医院麻醉科

Applicant's institution:

Department of Anesthesiology, Shantou Central Hospital

研究负责人所在单位:

汕头市中心医院麻醉科

Affiliation of the Leader:

Department of Anesthesiology, Shantou Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

【2022】科研002号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

汕头市中心医院医院伦理委员会

Name of the ethic committee:

Shantou Central Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2022-04-08 00:00:00

伦理委员会联系人:

杨春枝

Contact Name of the ethic committee:

Chunzhi Yang

伦理委员会联系地址:

中国广东省汕头市金平区外马路114号

Contact Address of the ethic committee:

114 Waima Road, Jingping District, Shantou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 754 89653326

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

汕头市中心医院

Primary sponsor:

Shantou Central Hospital

研究实施负责(组长)单位地址:

广东省汕头市金平区外马路114号

Primary sponsor's address:

114 Waima Road, Jingping District, Shantou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

汕头市中心医院

具体地址:

金平区外马路114号

Institution
hospital:

Shantou Central Hospital

Address:

114 Waima Road, Jingping District

国家:

中国

省(直辖市):

广东

市(区县):

汕头

Country:

China

Province:

Guangdong

City:

Shantou

单位(医院):

汕头市中心医院

具体地址:

广东省汕头市金平区外马路114号

Institution
hospital:

Shantou Central Hospital

Address:

114 Waima Road, Jingping District, Shantou, Guangdong, China

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

乳腺癌  

Target disease:

breast cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究通过将伤害性水平指数(NOX)应用于睡眠障碍患者乳腺癌根治术中,指导术中麻醉镇痛用药,观察围术期阿片类药物的使用量、患者认知功能及相应指标的变化,以评估NOX在睡眠障碍患者乳腺癌根治术中的应用价值。  

Objectives of Study:

In this study, the nociceptive level index ( NOX ) was applied to the radical mastectomy of breast cancer in patients with sleep disorders to guide the anesthetic and analgesic medication during the operation, and to observe the changes in the use of opioids, patients ’ cognitive function and corresponding the perioperative period, so as to evaluate the application value of NOX in the radical mastectomy of breast cancer in patients with sleep disorders.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

麻醉药物过敏;长期接受镇痛、镇静药物治疗史和吸毒史者;精神病病史或不合作者;心功能不全;心脏传导阻滞;呼吸衰竭,肾功能衰竭;活动性肝病患者;严重的视力或听力障碍者;文盲以及在语言上无法与医师沟通的患者;孕妇、残障人士。

Exclusion criteria:

Anesthesia drug allergy ; patients with long-term history of analgesic, sedative drug treatment and drug use ; patients with mental illness history or non-cooperation ; cardiac insufficiency ; cardiac block ; respiratory failure, renal failure ; patients with active liver disease ; patients with severe visual or hearing impairment ; illiteracy and patients who cannot communicate with doctors in language ; pregnant women, disabled persons.

研究实施时间:

Study execute time:

From 2022-12-01 00:00:00 To 2023-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-12-01 00:00:00 To 2023-12-01 00:00:00

干预措施:

Interventions:

组别:

组1

样本量:

30

Group:

Group 1

Sample size:

干预措施:

干预措施代码:

C

Intervention:

None

Intervention code:

组别:

组2

样本量:

30

Group:

Group 2

Sample size:

干预措施:

NOX指导

干预措施代码:

N

Intervention:

NOX Guided

Intervention code:

组别:

组3

样本量:

30

Group:

Group 3

Sample size:

干预措施:

胸神经阻滞+NOX指导

干预措施代码:

P

Intervention:

Thoracic nerve block and NOX Guided

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

汕头市中心医院 

单位级别:

公立三甲 

Institution
hospital:

Shantou Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

炎症因子

指标类型:

主要指标

Outcome:

inflammatory factor

Type:

Primary indicator

测量时间点:

术前、术后

测量方法:

酶联免疫吸附试验

Measure time point of outcome:

Preoperative and postoperative

Measure method:

ELISA

指标中文名:

认知功能

指标类型:

主要指标

Outcome:

cognitive function

Type:

Primary indicator

测量时间点:

术前、术后

测量方法:

酶联免疫吸附试验

Measure time point of outcome:

Preoperative and postoperative

Measure method:

ELISA

指标中文名:

肿瘤坏死因子-α

指标类型:

主要指标

Outcome:

TNF-α

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-6

指标类型:

主要指标

Outcome:

IL-6

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清星形胶质细胞S100蛋白的β亚型

指标类型:

主要指标

Outcome:

S-100β

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经元特异性烯醇化酶

指标类型:

主要指标

Outcome:

NSE

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

海马自噬体

指标类型:

主要指标

Outcome:

LC3-H

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Beclin-1

指标类型:

主要指标

Outcome:

Beclin-1

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

人体

Sample Name:

serum

Tissue:

human

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机方法由不参与操作与随访的护士采用计算机随机数法。

Randomization Procedure (please state who generates the random number sequence and by what method):

Methods A computer random number method was used by nurses who did not participate in the operation and follow-up.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

共享的公共平台为临床研究公共管理平台(ResMan), http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The public management platform for clinical research (ResMan), http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

(1)病例记录表; (2)电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(1)Case Record Form, CRF; (2)Electronic Data Capture, EDC1

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-29 21:41:59